Kyverna Therapeutics Financials - Benzinga

Kyverna Therapeutics Inc

KYTXNASDAQ

Trade with Public

Trade with Public

$6.81

-0.18-2.58%

가까이에: Sep 25, 5:00 PM EST

$6.80

-0.0076-0.11%

시간외: Sep 25, 7:51 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Kyverna Therapeutics Financials

Kyverna Therapeutics (KYTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share

Benzinga Newsdesk

PRO
Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.73) by 9.59 percent. This is a 35.92 percent increase over losses of $(1.03) per share

Benzinga Newsdesk

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.

Mohd Haider

PRO
Kyverna Therapeutics Q4 EPS $(0.80) Beats $(0.85) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.85) by 5.66 percent. This is a 8.11 percent decrease over losses of $(0.74) per share

Benzinga Newsdesk

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Avi Kapoor

Dow Jumps 150 Points; Jabil Posts Upbeat Earnings

Avi Kapoor

© 2026 Benzinga | All Rights Reserved